{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6800"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Maximally tolerated area under the curve of intravenous busulfan (Busulfan®) in combination with fludarabine as conditioning regimen for transplantation with in-vivo T-cell depletion. The number reported will be an Area Under the Curve (AUC) measure reported in µmol-min/L.","groups":[{"description":"Intravenous busulfan (Busulfan®) in combination with fludarabine\n\nBusulfan: Daily intravenous dosing to target AVC\n\nFludarabine: Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.\n\nCampath: All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).\n\nStem Cell Transplant: Infusion of bone marrow and donors(related/ unrelated).","id":"OG000","title":"Busulfan and Fludarabine"}],"paramType":"NUMBER","populationDescription":"The 36 patients refer to the phase I portion of the study only.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Maximum Tolerated Dose","type":"PRIMARY","unitOfMeasure":"mmol-min/L"}